Coherus Oncology (CHRS) Operating Income (2013 - 2026)
Coherus Oncology (CHRS) posted Operating Income of -$36.2 million for Q1 2026, up 21.21% sequentially from -$45.9 million in Q4 2025, and up 20.43% YoY from -$30.0 million in Q1 2025.
Coherus Oncology (CHRS) Operating Income (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Operating Income for 14 years, with the latest figure at -$36.2 million in Q1 2026.
- Quarterly Operating Income rose 20.43% year-over-year to -$36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.8 million (up 3.07% YoY) and the FY2025 annual result came in at -$181.1 million, up 9.28% from the prior year.
- Operating Income advanced to -$36.2 million in Q1 2026 per CHRS's latest filing, from -$45.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$32.0 million in Q3 2023 and troughed at -$80.9 million in Q1 2022.
- A 5-year average of -$51.6 million and a median of -$45.5 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income plunged 145.37% in 2022, then surged 60.22% in 2023.
- Over 5 years, Operating Income stood at -$51.5 million in 2022, then sank by 33.81% to -$68.9 million in 2023, then soared by 34.14% to -$45.4 million in 2024, then fell by 1.09% to -$45.9 million in 2025, then grew by 21.21% to -$36.2 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$36.2 million, -$45.9 million, and -$44.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 133.12 Mn |
| 10 | Coherus Oncology | 218.29 Mn | 112.99 Mn | 10.07 Mn | -32.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.33 Mn |
| Mar 31, 2026 | -36.15 Mn |
| Dec 31, 2025 | -45.88 Mn |
| Sep 30, 2025 | -44.33 Mn |
| Jun 30, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.44 Mn |
| Dec 31, 2024 | -45.38 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Jun 30, 2024 | -39.63 Mn |
| Mar 31, 2024 | -67.79 Mn |
| Dec 31, 2023 | -68.91 Mn |
| Sep 30, 2023 | -32.01 Mn |
| Jun 30, 2023 | -34.54 Mn |
| Mar 31, 2023 | -67.75 Mn |
| Dec 31, 2022 | -51.49 Mn |
| Sep 30, 2022 | -80.45 Mn |
| Jun 30, 2022 | -44.01 Mn |
| Mar 31, 2022 | -80.93 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -32.79 Mn |